A U.S. innovation engine. Open to global collaboration.
GenREY is engineered as a U.S. innovation engine — research, IP development and early commercialization — and is open to international collaboration with the institutional partners who can take that platform into national-scale clinical and manufacturing deployment.
American biotechnology has unmatched depth in early-stage discovery, capital markets and trial infrastructure. The right international partners bring complementary strengths — manufacturing localisation, sovereign-grade clinical adoption, ministerial alignment and patient-recruitment scale. GenREY is built to be a credible, science-first counterpart to those partners, not to claim them in advance.
On the U.S. side, our base is Texas, United States, with a translational platform spanning iREY, DAMI delivery, stem-cell and exosome biology, genomic intelligence and a translational laboratory pipeline. We engage academic medical centres, surgical specialties and translational research networks where the science fits — invitation-led, not imposed.
Internationally, we are open to collaboration with sovereign funds, ministries of health, national research institutes, regional health systems and life-sciences platforms. Where a fit emerges, the engineering is portable: IP filings designed to move, manufacturing playbooks designed to localise, clinical protocols designed to harmonise across regulatory authorities.
U.S. innovation, designed to integrate with the partners who scale it.
GenREY runs as a U.S. innovation engine — research, IP and early commercialization — and is open to international collaboration with the institutional partners who can take that platform into national clinical and manufacturing deployment.
Research · IP · Early commercialization
- · Texas, United States
- · Translational science engine
- · Patent-pending iREY / DAMI platform
- · Regulatory navigation (FDA pathway)
IP licensing · Tech transfer · Clinical collaboration · Manufacturing localisation — partner-led, jurisdiction-specific.
Manufacturing · Deployment · Capacity
- · Open to sovereign and ministerial partners
- · Open to academic medical centres globally
- · Open to pharma and licensing collaborators
- · Jurisdiction-specific manufacturing localisation
Platform-grade biotechnology
IP, formulations, devices and data architectures engineered to be portable across jurisdictions and resilient at scale.
Closed-loop translation
A dual-engine model: a grant-funded scientific engine generating IP, paired with a commercial translation engine deploying clinical and consumer products.
Vertical integration
Discovery → IP → Validation → Clinical → Manufacturing → Deployment — under one regenerative platform optimized for partner-led scale.
Recurring economics
Premium device sales, consumable serum and cartridge subscriptions, clinic partnerships, licensing and white-label biotech revenue — built for durable cashflow.
Where to next?
Continue exploring how GenREY translates science into platform-grade biotechnology.